tbuckley/cabot-search huggingface dataset:
P11.11 Aggressive Meningiomas: In vitro study of the combination pasireotide-everolimus vs. octreotide everolimus
Authors: T. Graillon, D. Romano, C. Defilles, D. Figarella-Branger, P. Roche, H. Dufour, O. Chinot, A. Barlier
Journal: Neuro-Oncology (2016)

To date, no drug has clearly demonstrated its efficacy in aggressive and recurrent meningiomas. We have previously demonstrated the interest of the combination of octreotide (somatostatin agonist) and everolimus (mTOR inhibitor) in meningiomas, allowing the establishment of a clinical trial. The pasireotide is a pansomatostatin agonist targeting SST1, SST2, SST3 and SST5 receptors while octreotide only targets SST2 receptor. Pasireotide is more stable than octreotide and allows a different mode of SST2 receptors internalization, increasing SST2 membrane expression. In other types of tumors (pituitary adenomas and neuroendocrine tumors), a better effect of pasireotide compared to octreotide has been demonstrated. The aim of this in vitro study is to compare the effect of pasireotide and octreotide alone or in combination with everolimus to determine the potential interest of a clinical trial with pasireotide-everolimus. The expression of SST receptors was analyzed by real-time PCR. The impact of drugs on cell viability and on the PI3K- Akt-mTOR pathway was analyzed in 70 tumors placed in primary culture immediately after surgical resection. SST2 is expressed in the 30 tumors tested, SST1 in 40.5% and in 35% SST5. Among 48 analyzed tumors, anti-proliferative effect of pasireotide was stronger compared to octreotide and appears related to the expression of SST1. Pasireotide quite provides a stronger inhibitory effect on the PI3K-Akt and on the cell-cycle proteins compared to octreotide. The additive effect of the combination pasireotide-everolimus is more powerful than the combination octreotide-everolimus. All our in vitro results underline the importance of pasireotide-everolimus vs. octreotide-everolimus combination, suggesting clinical interest for aggressive meningiomas.
Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Authors: Irene Ricca, Daniela Drandi, Alberto Rocci, Mara Compagno, Roberto Francese, Barbara Mantoan, Claudia Castellino, Francesca Ficara, Sonia Vallet, Maria Dell’Aquila, Loredana Santo, Daniele Caracciolo, Luciana Bergui, Andrea Gallamini, Mario Bazzan, Carlo Marinone, Mario Boccadoro, Corrado Tarella, Marco Ladetto
Journal: Blood (2004)
HPFH From Klf1 Haploinsufficiency Combined to Transcriptional Heterozygous β-Thalassemia
Authors: Paolo Moi, Giuseppina M. Marini, Isadora Asunis, Loredana Porcu, Annalisa Cabriolu, Stefania Satta, Luciana Perseu, Liliana Maccioni, Antonio Cao, Renzo Galanello
Journal: Blood (2011)
Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).
Authors: Arnold S. Freedman, Paul A. Hamlin, Sattva Neelapu, Craig Nichols, Michael Robertson, Gregoire Bergier, Jane N. Winter, Jonathan Polikoff, Thomas Lin, Brad Pohlman, Vanessa Esquibel, Teresa Melink, John Bender
Journal: Blood (2006)
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study
Authors: D. Schadendorf, A. Hauschild, S. Fosko, D. Zloty, B. Labeille, J.J. Grob, S. Puig, M. Makrutzki, I. Templeton, G. Rogers, B. Dreno, R. Kunstfeld
Journal: Annals of Oncology (2016)
Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy
Authors: Ruqi Tang, Yiran Wei, Yanmei Li, Weihua Chen, Haoyan Chen, Qixia Wang, Fan Yang, Qi Miao, Xiao Xiao, Haiyan Zhang, Min Lian, Xiang Jiang, Jun Zhang, Qin Cao, Zhuping Fan, Maoying Wu, Dekai Qiu, Jing-Yuan Fang, Aftab Ansari, M Eric Gershwin, Xiong Ma
Journal: Gut (2017)

Objective A close relationship between gut microbiota and some chronic liver disorders has recently been described. Herein, we systematically performed a comparative analysis of the gut microbiome in primary biliary cholangitis (PBC) and healthy controls. Design We first conducted a cross-sectional study of 60 ursodeoxycholic acid (UDCA) treatment-naïve patients with PBC and 80 matched healthy controls. Second, an independent cohort composed of 19 treatment-naïve patients and 34 controls was used to validate the results. Finally, a prospective study was performed in a subgroup of 37 patients with PBC who underwent analysis before and after 6 months of UDCA treatment. Faecal samples were collected, and microbiomes were analysed by 16S ribosomal RNA gene sequencing. Results A significant reduction of within-individual microbial diversity was noted in PBC (p=0.03). A signature defined by decreased abundance of four genera and increased abundance of eight genera strongly correlated with PBC (area under curve=0.86, 0.84 in exploration and validation data, respectively). Notably, the abundance of six PBC-associated genera was reversed after 6 months of UDCA treatment. In particular, Faecalibacterium , enriched in controls, was further decreased in gp210-positive than gp210-negative patients (p=0.002). Of interest was the finding that the increased capacity for the inferred pathway, bacterial invasion of epithelial cells in PBC, highly correlated with the abundance of bacteria belonging to Enterobacteriaceae . Conclusions This study presents a comprehensive landscape of gut microbiota in PBC. Dysbiosis was found in the gut microbiome in PBC and partially relieved by UDCA. Our study suggests that gut microbiota is a potential therapeutic target and diagnostic biomarker for PBC.
Trastuzumab Based Chemotherapy in Two Patients with HER2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma
Authors: Yohei Arihara, Kazuyuki Murase, Kohichi Takada, Naotaka Hayasaka, Shogo Miura, Koji Miyanishi, Masayoshi Kobune, Makoto Kurose, Yukinori Akiyama, Junji Kato
Journal: Annals of Oncology (2016)
MNGO-16. FETAL MICROCHIMERISM IN HUMAN BRAIN TUMORS
Authors: Lauren Broestl, Joshua Rubin, Sonika Dahiya
Journal: Neuro-Oncology (2016)

Sex differences in cancer incidence and survival are well documented in many epidemiological studies. Multiple cellular and organismal mechanisms contribute to sex differences in health and disease. Recently, the presence of fetal-in-maternal microchimeric cells has been shown to have prognostic significance in breast and colorectal cancers. The frequency and potential role of these cells has thus far not been investigated in brain tumors. We therefore selected two common primary brain tumors in adults for this purpose: meningioma, which is sex hormone responsive and has a higher incidence in women, and glioblastoma, which is sex hormone independent and occurs slightly more commonly in men. Institutional review board approval was obtained, and thirty cases of glioblastoma and 26 meningiomas were identified in female patients with a known obstetric history positive for male birth. In addition, tumors from male patients (n=4), and women with known absence of male pregnancy (n=4) were used as controls. Fluorescence in situhybridization was performed on archived formalin-fixed paraffin embedded material to detect the presence of Y chromosome (Yq12; Satellite III). A total number of 2000 cells were counted. Three women in each of the two groups (glioblastoma; n=30, and meningioma; n=26) were found to have XY cells in their tumors. We have determined, for the first time that fetal microchimerism occurs in primary brain tumors. Fetal microchimeric cells appear to be present in approximately 10% of brain tumors and this may be independent of tumor type. Additional work will be needed to determine whether this is true in other primary and secondary CNS neoplasms and what role these cells may play in tumor biology.
Characterization of Bortezomib Resistant Human Multiple Myeloma Cell Line (HMCL): A Clinically Relevant Model for Novel Drug Development in Multiple Myeloma (MM).
Authors: Asher Alban Chanan-Khan, Noreen Ersing, Paula Pera, Ralph Bernaki, Lionel Coignet, David W. Goodrich, Raya Haung, Carl W. Porter
Journal: Blood (2006)
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the <scp>RELAX</scp> trial
Authors: Adam D. DeVore, Steven McNulty, Fawaz Alenezi, Mads Ersboll, Justin M. Vader, Jae K. Oh, Grace Lin, Margaret M. Redfield, Gregory Lewis, Marc J. Semigran, Kevin J. Anstrom, Adrian F. Hernandez, Eric J. Velazquez
Journal: European Journal of Heart Failure (2017)
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Authors: B. Shah, J. Castro, N. Gökbuget, M. José Kersten, T. Hagenbeek, W. Wierda, G. Schiller, A. Bot, J.M. Rossi, Y. Jiang, L. Navale, S. Stout, J. Aycock, J. Wiezorek, R. Jain
Journal: Annals of Oncology (2016)
Reply: Antigens of Chemically Induced Colon Tumors in Rats
Authors: Calvin A. Saravis
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Reply: Antigens of Chemically Induced Colon Tumors in Rats Get access Calvin A. Saravis, Ph.D. Calvin A. Saravis, Ph.D. Mallory Institute of Pathology Foundation, Boston, Massachusetts 02115. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 2, February 1976, Page 212, https://doi.org/10.1093/jnci/56.2.212-a Published: 01 February 1976
HPV status in relation to clinicopathologic variables in patients with penile cancer at Los Angeles County-USC Medical Center.
Authors: Rachel L. Schwartz, Isuru Sampath Jayaratna, Anirban Pradip Mitra, Diane Da Silva, W Martin Kast, Moli Chen, Yanling Ma, David I. Quinn, Tanya B. Dorff, Anne Schuckman
Journal: Journal of Clinical Oncology (2012)

329 Background: Penile squamous cell carcinoma (PSCC) is a disfiguring and deadly disease. US cancer registry reports a higher incidence in certain minority communities including those over-represented at LAC-USC. Human papilloma virus (HPV) infection is strongly associated with PSCC. This study examined correlations of HPV presence and subtype with PSCC patient clinicopathological variables. Methods: After IRB approval, a retrospective review of PSCC patients at LAC-USC between 1996-2010 was completed. HPV presence and genotype was detected from primary tumors of 33 patients by DNA amplification followed by reverse line blot hybridization. Associations with patient and tumor characteristics were examined by contingency analyses. Results: 20 (60.6%) patients were HPV+, and 85% of all HPV+ cases harbored at least one high-risk viral strain (80% of all positive cases had HPV 16, 5% HPV 31, 10% HPV 66). 20% of all positive cases harbored low-risk HPV 11; HPV strains 6 or 35 were not detected in any specimen. 3 patients were positive for multiple strains. Overall median age at diagnosis was 53 (range: 24-77) yrs. Median age was 56 yrs and 49 yrs for HPV+ and HPV- patients, respectively. HPV infection showed a trend towards being more prevalent in patients beyond the fifth decade of life, although this did not reach statistical significance (p=0.10). 22 (66.7%) patients were Hispanic; this ethnicity comprised 60% and 77% of HPV+ and HPV- cases, respectively (p=0.31). This cohort included Stage 0 (n= 1, n= 0), Stage 1 (n= 4, n=2), Stage 2 (n= 4, n= 4), Stage 3 (n=5, n= 1), and Stage 4 (n= 4, n= 5) HPV+ and HPV- patients, respectively. Neither HPV status nor presence of nodal metastasis was significantly associated with stage (p=0.50, p=0.52 respectively). Tumor grade was available for 30 (90.9%) cases; while HPV+ cases tended to have higher proportion of moderately-poorly differentiated tumors than HPV- cases (77.8% vs. 58.3%), this was not statistically significant (p=0.32). Conclusions: An overwhelming majority of HPV+ cases harbored at least one high-risk viral strain. Several interesting associations of HPV status with age and grade were noted, although the study was underpowered to show significance.
Quantitative Comparison of BCR/ABL Transcript Levels in Bone Marrow and Peripheral Blood Specimens from Patients with Minimal Residual Disease.
Authors: Nicole E. Faulkner, D. Alexa Sirko-Osadsa, Lynne S. Rosenblum-Vos, Elizabeth M. Rohlfs, Patrick Browne, Stephanie E. Hallam
Journal: Blood (2005)
Efficacy and Effectiveness of Azacitidine In Elderly Patients with Acute Myeloid Leukemia and Blasts Counts below 30%: Experience of the Spanish Registry
Authors: Regina García, Monserrat Arnar, Elisa Luño, Joan Bargay, Ma Mar Romero, Juan Besalduch, Elena Amutio, Raquel Garrido, Fernando Carnicero, Grupo Andaluz de Smd
Journal: Blood (2010)
Tolerability of modified gemcitabine/docetaxel (split-dose) in patients with advanced soft tissue sarcomas
Authors: R.G.M.V.D. Azevedo, N. Fraile, E. Saadi Neto, R.V.M. Lopez, D. Toloi, P.M. Hoff, O. Feher, V.P.D. Camargo, R. Munhoz
Journal: Annals of Oncology (2016)
Rapid Duffy Genotyping in Sickle Cell Disease Patients Using PCR-SSP Is a Valuable Tool for Blood Component Selection.
Authors: Marcia C.Z. Novaretti, Silvia L. Bonifacio, Vitor R. Medeiros, Sandra F.M. Gualandro, Pedro E. Dorlhiac-Llacer, Dalton A.F. Chamone
Journal: Blood (2007)
NIMG-08. PREDICTION OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MALIGNANT GLIOMA USING DYNAMIC O-(2-18F-FLUOROETHYL)-L-TYROSINE PET
Authors: Norbert Galldiks, Elena Bauer, Gabriele Stoffels, Tobias Blau, Guido Reifenberger, Jörg Felsberg, Marion Rapp, Michael Sabel, Gereon Fink, Nadim Shah, Karl-Josef Langen
Journal: Neuro-Oncology (2016)

The individual clinical course of high-grade gliomas (HGG) may vary considerably and can often be unpredictable. Thus, we investigated the prognostic value of dynamic O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed astrocytic HGG. Before initiation of treatment, dynamic FET PET imaging was performed in patients with newly diagnosed glioblastoma and anaplastic astrocytoma. Static FET PET parameters such as maximum and mean tumor/brain ratios (TBRmax/mean) as well as the dynamic FET PET parameter time-to-peak (TTP) were obtained. The predictive ability of FET PET parameters was evaluated with regard to progression-free survival (PFS). Using receiver-operating characteristic curve (ROC) analyses, threshold values for FET PET parameters were obtained. Subsequently, univariate Kaplan-Meier and multivariate Cox regression survival analyses were performed to assess their predictive power for PFS. One hundred and one patients (58 glioblastomas, 43 anaplastic astrocytomas) of two university centers were retrospectively identified. Forty-seven of 101 patients (mean age, 55 ± 16 years) were eligible for data evaluation. Patients with a methylated MGMT promoter as well as with an IDH-1 mutation had a significantly longer PFS (P = 0.03 and P = 0.003, respectively). Furthermore, ROC analysis revealed that a TTP > 32.5 min (AUC, 0.77; sensitivity, 75%; specificity, 74%; P = 0.019) was highly prognostic for a longer PFS (7 mo vs. 19 mo; P < 0.001). IDH-1 and TTP remained significant in the multivariate survival analysis (P = 0.05 and P = 0.008, respectively), indicating independent predictors for PFS. In contrast, both TBRmax and TBRmean derived from static imaging were not prognostic (AUC, 0.44 and 0,5, respectively). FET PET may predict PFS in patients with newly diagnosed and untreated HGG, with dynamic analysis showing advantages over static imaging.
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
Authors: A.J. Wagner, H. Kindler, H. Gelderblom, P. Schöffski, S. Bauer, P. Hohenberger, H.-G. Kopp, J.A. Lopez-Martin, M. Peeters, P. Reichardt, A. Qin, J. Nippgen, R.L. Ilaria, P. Rutkowski
Journal: Annals of Oncology (2016)

This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively).Patients received olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity occurred. Outcome measures were 12-week tumor response, progression-free survival (PFS), overall survival (OS), and safety.Of 30 patients enrolled, 21 patients received ≥1 dose of olaratumab. In the evaluable population (cohort 1, n = 6; cohort 2, n = 14), no complete response (CR) or partial response (PR) was observed. Stable disease (SD) was observed in 3 patients (50.0%) in cohort 1 and 2 patients (14.3%) in cohort 2. Progressive disease (PD) was observed in 3 patients (50.0%) in cohort 1 and 12 patients (85.7%) in cohort 2. The 12-week clinical benefit rate (CR + PR + SD) (90% CI) was 50.0% (15.3-84.7%) in cohort 1 and 14.3% (2.6-38.5%) in cohort 2. SD lasted beyond 12 weeks in 5 patients (cohort 1, n = 3; cohort 2, n = 2). Median PFS (90% CI) was 32.1 (5.0-35.9) weeks in cohort 1 and 6.1 (5.7-6.3) weeks in cohort 2. Median OS was not reached in cohort 1 and was 24.9 (14.4-49.1) weeks in cohort 2. All patients in cohort 1 and 9 (64.3%) in cohort 2 experienced an olaratumab-related adverse event (AE), most commonly fatigue (38.1%), nausea (19.0%), and peripheral edema (14.3%). Two grade ≥3 olaratumab-related events were reported (cohort 1, syncope; cohort 2, hypertension).Olaratumab had an acceptable AE profile in patients with GIST. While there was no apparent effect on PFS in patients without PDGFRα mutations, patients with PDGFRα-mutant GIST (all with D842V mutations) treated with olaratumab had longer disease control compared with historical data for this genotype.NCT01316263.
P01.07 Identification of novel molecular targets for TMZ-based therapies against glioblastoma: A comprehensive shRNA-based screen of DNA Damage Response factors
Authors: H. Erasimus, S. Fritah, S. Haan, C. Herold-Mende, B. Klink, J. Y. Masson, P. V. Nazarov, S. P. Niclou, E. Van Dyck
Journal: Neuro-Oncology (2016)
NCOG-05. THE USE OF STRATEGIES TO COMPENSATE FOR COGNITIVE, BEHAVIORAL AND EMOTIONAL CHANGES AFTER A PRIMARY BRAIN TUMOR
Authors: Eng-Siew Koh, Diane Whiting, Wafa Trad, Lauren Gillett, Teresa Simpson, Grahame Simpson
Journal: Neuro-Oncology (2016)

Changes have been reported to cognitive, behavioural and emotional functioning among patients with primary brain tumour (PBT). It is not known though, whether individuals are utilising strategies to compensate for these changes. This study sought to measure individuals’ strategy use to manage changes after the onset of a PBT and whether this changed from pre- to post-diagnosis. Individuals (n= 38) with an average age of 52.6 years and diagnosed with a PBT were administered the Strategy Use Measure (SUM) on average 37.6 months (SD=49.0) post diagnosis. Individuals were at various stages of the treatment phase and were across the spectrum of PBT type. The SUM is a 14 item self-report measure that assesses strategy use pre and post diagnosis on a five-point Likert scale (total score range 0-56). In addition to the total score, there are three sub-scales, namely Memory and Planning (MP, 5 items), Emotion and Mood (EM, 5 items) and Cognitive Load (CL, 4 items). It has been validated on an acquired brain injury population (including PBT) and subscales have good reliability (Cronbach’s alpha ranges from .82-.83). Individuals with PBT reported a significant increase in strategy use (t-tests, all p<.001) from pre to post diagnosis across all three sub scales of the SUM (MP, pre 9.42 ± 4.7, post 14.71 ± 6.0; EM, pre 5.53 ± 4.0, post 9.82 ± 4.0; CL, pre 3.84 ± 3.3, post 10.32 ± 3.6) and for total strategy use (pre 18.8 ± 10.7, post 34.8 ± 11.5). The highest reported increase was on the subscale that assessed the management of cognitive load and the highest individual item endorsed was managing fatigue. The SUM demonstrates that clients significantly increase their strategy use in an attempt to manage the cognitive, emotional and behavioural changes post-PBT. The SUM can help measure the efficacy of interventions that seek to increase strategy use after PBT.
Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation
Authors: Elien Gevaert, Nan Zhang, Olga Krysko, Feng Lan, Gabriële Holtappels, Natalie De Ruyck, Hans Nauwynck, Shida Yousefi, Hans-Uwe Simon, Claus Bachert
Journal: Journal of Allergy and Clinical Immunology (2017)
P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study
Authors: A. Alentorn, C. Carpentier, K. Labreche, F. Ducray, C. Dehais, K. Mokhtari, E. Uro-Coste, D. Figarella-Branger, J. Delattre, A. Idbaih
Journal: Neuro-Oncology (2016)
Agnostos precision medicine project: a multicenter clinical and translational initiative in patients (PTS) with cancer of unknown primary (CUP)
Authors: E. Geuna, S. Benvenuti, F. Verginelli, D. Galizia, G. Cerea, G.M. Stella, A. Ardizzoni, L. Ciuffreda, G. Curigliano, F.G. De Braud, A. Gennari, G. Tonini, A. Brunello, P. Cassoni, R. Senetta, A. Sapino, S. Marsoni, C. Boccaccio, P.M. Comoglio, F. Montemurro
Journal: Annals of Oncology (2016)
ACTR-43. PILOT STUDY OF OPTUNE (NOVOTTF-100A) FOR RECURRENT ATYPICAL AND ANAPLASTIC MENINGIOMA
Authors: Synphen Wu, Igor Gavrilovec, Macarena Ines De La Fuente, Teri Kreisl, Thomas Kaley
Journal: Neuro-Oncology (2016)

Medical therapies for surgery and radiotherapy-refractory meningiomas are limited. Optune (NovoTTF-100A) is an external cranial device that produces low intensity, intermediate frequency, alternating electric fields that interfere with cell division and stunt tumor cell growth. Although it is FDA-approved for use in recurrent glioblastoma, its efficacy in recurrent meningioma is unknown. We conducted a pilot study for patients with recurrent atypical and anaplastic meningioma (WHO grades II–III). Optune is initiated as monotherapy for ≥ 18 hours per day per the established treatment standard. MRI scans are performed every 8 weeks. The primary endpoint is the 6-month progression-free survival (PFS) rate, with secondary endpoints of time to progression, radiographic response, safety and tolerability, overall survival (OS) rate, and volumetric and MR-perfusion correlates. To date, 6 patients (3 female) with a median age of 60.4 years (range 27.5–70.2 years) and median KPS of 70 (range 60–100%) have been enrolled. Histologies include 3 recurrent WHO grade II atypical and 3 recurrent WHO grade III anaplastic meningiomas. Median number of recurrences was 5 (range 2–12). All patients had failed prior surgery and radiation. Median PFS was 3.3 months (range 1.0–4.6 months). Best radiographic response was SD (n=4) and PD (n=2); no patient achieved PR or CR. Treatment was well tolerated with no grade 3, 4, or 5 toxicities. Notable toxicities at least possibly related to treatment include: grade 2 skin ulceration (n=2), grade 2 fatigue (n=1), and grade 1 fatigue (n=1). Five patients discontinued treatment due to disease progression; one patient withdrew consent. Median duration of the treatment was 3.7 months (range 1.0–4.6 months). In this heavily pretreated population, 4 of 6 patients attained SD with Optune treatment. Trial accrual is ongoing.
IDH1 and IDH2 Mutations In Pediatric Acute Myeloid Leukemia
Authors: Anna Andersson, David Miller, John Lynch, Andrew Lemoff, Zhongling Cai, Stanley Pounds, Ina Radtke, Yan Bing, Schuetz John, Rubnitz Jeffrey, Raul Ribeiro, Susana C. Raimondi, Jinghui Zhang, Sheila Shurtleff, Brenda Schulman, James Downing
Journal: Blood (2010)